Cargando…
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
BACKGROUND: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is p...
Autores principales: | Hinnen, Deborah, Kruger, Davida F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452802/ https://www.ncbi.nlm.nih.gov/pubmed/31040709 http://dx.doi.org/10.2147/DMSO.S188705 |
Ejemplares similares
-
Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
por: Deed, Gary, et al.
Publicado: (2019) -
Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes
por: Oost, Lynette J, et al.
Publicado: (2022) -
Cardiovascular outcomes in type 1 and type 2 diabetes
por: Rosengren, Annika, et al.
Publicado: (2023) -
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
por: Williams, David M., et al.
Publicado: (2019) -
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)